The research of anti-inflammatory, endothelioprotective and cardioprotective activity of 3-hydroxy-3-methylglutaryl-CoA reductase simvastatine in L-NAME-induced nitric oxide deficiency in experiment was carried out. Results of research proved the presence of simvastatin's expressive anti-inflammatory, endothelioprotective and cardioprotective effects. The most expressive correction of endothelial dysfunction is observed in use of simvastatin in a dose 8,6 mg/kg. Cardiac load-carrying tests also revealed significant cardioprotective activity in use of simvastatin in a dose 8,6 mg/kg.
Research of anti-inflammatory, endothelioprotective, cardioprotective activity of inhibitor of 3-gidroksi-3-metilglutaril-CoA reductase atorvastatin in experiments on mice and rats was carried out. The received results have allowed to establish the presence of expressed dosagedependent anti-inflammatory activity of atorvastatin. The expressed correction of endothelial dysfunction at application of atorvastatin in a dose of 2.2 mg/kg is evident Thus application of atorvastatin in a dose of 8.6 mg/kg has not led to authentically more expressed decreasing of endothelial dysfunction, in comparison with a dose of 2.2 mg/kg. At carrying out of loading tests it is established the expressed cardioprotective activity of atorvastatin in a dose of 2.2 mg/kg.
The study endothelial and cardioprotective effects of antioxidants in modeling L-NAME-induced deficiency of nitric oxide. The results obtained allowed to establish express edendothelial dysfunction and prevention adrenoreactivity increasea and decrease of myocardial reserve in the experiment with the use of drugs ethoxidol 25 mg/kg resveratrol 2 mg/kg and mexidol 60 mg/kg. In this case, use of the drug resveratrol led to a significantly more pronounced reduction coefficient of endothelial.
At the laboratory of the Cardiofarmacology Scientific Research Institute of Ecological medicine endothelioprotective, cardioprotective activity of inhibitor of 3-gidroksi-3-metilglutaril-CoA reductase simvastatin and its combinations with L-arginin and resveratrol were investigated in experiments on rats. The received results have shown the presence of expressed endothelioprotective effects, amplifying with additional introduction of L-arginin and resveratrol at simvastatin The most expressed correction of endothelial dysfunction is observed in application of simvastatin in a combination with L-arginin. Warm loading tests have revealed more expressed cardioprotective activity of simvastatin, in comparison with its combinations with L-arginin and resveratrol.